Abstract
The impact of genetic variants in telomere pathway genes on telomere length and breast cancer survival remains unclear. We hypothesized that telomere length and genetic variants of telomere pathway genes are associated with survival among breast cancer patients. A population-based cohort study of 1,026 women diagnosed with a first primary breast cancer was conducted to examine telomere length and 52 genetic variants of 9 telomere pathway genes. Adjusted Cox regression analysis was employed to examine associations between telomere length, genetic variants and all-cause and breast cancer-specific mortality. Longer telomere length was significantly correlated with all-cause mortality in the subgroup with HER-2/neu negative tumors (HR = 1.90, 95 % CI: 1.12–3.22). Carrying the PINX1-33 (rs2277130) G-allele was significantly associated with increased all-cause mortality (HR = 1.45, 95 % CI: 1.06–1.98). Three SNPs (TERF2-03 rs35439397, TERT-14 rs2853677, and TERT-67 rs2853669) were significantly associated with reduced all-cause mortality. A similar reduced trend for breast cancer-specific mortality was observed for carrying the TERT-14 (rs2853677) T-allele (HR = 0.57, 95 % CI: 0.39–0.84), while carrying the POT1-18 (rs1034794) T-allele significantly increased breast cancer-specific mortality (HR = 1.48, 95 % CI: 1.00–2.19). However, none of the associations remained significant after correction for multiple tests. A significant dose–response effect was observed with increased number of unfavorable alleles/genotypes (PINX1-33 G-allele, POT1-18 T-allele, TERF2-03 GG, TERT-14 CC, and TERT-67 TT genotypes) and decreased survival. These data suggest that unfavorable genetic variants in telomere pathway genes may help to predict breast cancer survival.
Similar content being viewed by others
Abbreviations
- 95 % CI:
-
95 % Confidence interval
- BMI:
-
Body mass index
- ER:
-
Estrogen receptor
- HR:
-
Hazard ratio
- ICD:
-
International Classification of Diseases
- LIBCSP:
-
Long Island Breast Cancer Study Project
- PINX1 :
-
PIN2-interacting protein 1
- POT1 :
-
Protection of telomeres
- PR:
-
Progesterone receptor
- Q-PCR:
-
Quantitative PCR
- SNP:
-
Single nucleotide polymorphism
- TERF2 :
-
Telomeric repeat binding factor 2
- TERT :
-
Telomerase reverse transcriptase
References
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60:277–300
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978
Morrow PK, Hortobagyi GN (2009) Management of breast cancer in the genome era. Annu Rev Med 60:153–165
Hsieh SM, Lintell NA, Hunter KW (2006) Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer. Breast Dis 26:157–162
Hunter KW (2004) Host genetics and tumour metastasis. Br J Cancer 90:752–755
Peterson NB, Beeghly-Fadiel A, Gao YT, Long J, Cai Q, Shu XO, Zheng W (2009) Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival. Int J Cancer 125:844–850
Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, Caldas C, Dunning A, Easton D, Ponder B, Pharoah P (2007) Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25:3015–3023
Udler MS, Azzato EM, Healey CS, Ahmed S, Pooley KA, Greenberg D, Shah M, Teschendorff AE, Caldas C, Dunning AM, Ostrander EA, Caporaso NE, Easton D, Pharoah PD (2009) Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 125:2687–2696
Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119:701–705
Grimm C, Kantelhardt E, Heinze G, Polterauer S, Zeillinger R, Kolbl H, Reinthaller A, Hefler L (2009) The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study. BMC Cancer 9:78
Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C (2010) Molecular profiling: moving away from tumor philately. Sci Transl Med 2:47ps43
Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245–R262
Blackburn EH (1991) Structure and function of telomeres. Nature 350:569–573
De Boeck G, Forsyth RG, Praet M, Hogendoorn PC (2009) Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 217:327–344
Salhab M, Jiang WG, Newbold RF, Mokbel K (2007) The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. Breast Cancer Res Treat 109:35–46
Svenson U, Nordfjall K, Stegmayr B, Manjer J, Nilsson P, Tavelin B, Henriksson R, Lenner P, Roos G (2008) Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 68:3618–3623
Varadi V, Brendle A, Brandt A, Johansson R, Enquist K, Henriksson R, Svenson U, Tavelin B, Roos G, Hemminki K, Lenner P, Forsti A (2009) Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis. Eur J Cancer 45:3008–3016
Bisoffi M, Heaphy CM, Griffith JK (2006) Telomeres: prognostic markers for solid tumors. Int J Cancer 119:2255–2260
Svenson U, Roos G (2009) Telomere length as a biological marker in malignancy. Biochim Biophys Acta 1792:317–323
Zhou X, Meeker AK, Makambi KH, Kosti O, Kallakury BV, Sidawy MK, Loffredo CA, Zheng YL (2012) Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence. Carcinogenesis 33:113–118
Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD (2007) Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev 16:1803–1811
Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Wolff MS, Stellman SD, Kabat GC, Levin B, Bradlow HL, Hatch M, Beyea J, Camann D, Trent M, Senie RT, Garbowski G, Maffeo C, Montalvan P, Berkowitz GS, Kemeny M, Citron C, Schnabel F, Schuss A, Hajdu S, Vinceguerra V, Collman GW, Obrams G (2002) The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to indentify environmental risk factors for breast cancer. Breast Cancer Res Treat 74:235–254
Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, Wallenstein S, Bradshaw PT, Garbowski G, Teitelbaum SL, Neugut AI, Santella RM, Chen J (2010) BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 121:685–692
Gammon MD, Santella RM, Neugut AI, Eng SM, Teitelbaum SL, Paykin A, Levin B, Terry MB, Young TL, Wang LW, Wang Q, Britton JA, Wolff MS, Stellman SD, Hatch M, Kabat GC, Senie R, Garbowski G, Maffeo C, Montalvan P, Berkowitz GS, Kemeny M, Citron M, Schnabel F, Schuss A, Hajdu S, Vinceguerra V (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677–685
Andrew T, Aviv A, Falchi M, Surdulescu GL, Gardner JP, Lu X, Kimura M, Kato BS, Valdes AM, Spector TD (2006) Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected female sibling pairs. Am J Hum Genet 78:480–486
Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622
Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J (2005) Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37:977–990
Savage SA, Stewart BJ, Liao JS, Helman LJ, Chanock SJ (2005) Telomere stability genes are not mutated in osteosarcoma cell lines. Cancer Genet Cytogenet 160:79–81
Shen J, Gammon MD, Wu HC, Terry MB, Wang Q, Bradshaw P, Teitelbaum SL, Neugut AI, Santella RM (2010) Multiple genetic variants in telomere pathway genes and breast cancer risk. Cancer Epidemiol Biomark Prev 19:219–228
Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Res 30:e47
Shen J, Gammon MD, Terry MB, Wang Q, Bradshaw P, Teitelbaum SL, Neugut AI, Santella RM (2009) Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer 124:1637–1643
Cox DG, Canzian F (2001) Genotype transposer: automated genotype manipulation for linkage disequilibrium analysis. Bioinformatics 17:738–739
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK (2006) Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 99:193–202
Cawthon RM (2009) Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 37:e21
Liu HQ, An JZ, Liu J, Yang YF, Zhang HX, Zhao BY, Li JB, Yang HS, Chen ZN, Xing JL (2012) Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis. doi:10.1093/carcin/bgs098
Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R (2011) A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res 13:R117
Weng NP (2008) Telomere and adaptive immunity. Mech Ageing Dev 129:60–66
Hodes RJ, Hathcock KS, Weng NP (2002) Telomeres in T and B cells. Nat Rev Immunol 2:699–706
Hsu CP, Hsu NY, Lee LW, Ko JL (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter—effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42:1466–1474
Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, Yasui W (2004) Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 64:523–529
Elkak A, Mokbel R, Wilson C, Jiang WG, Newbold RF, Mokbel K (2006) hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. Anticancer Res 26:4901–4904
Lin J, Jin R, Zhang B, Yang PX, Chen H, Bai YX, Xie Y, Huang C, Huang J (2007) Characterization of a novel effect of hPinX1 on hTERT nucleolar localization. Biochem Biophys Res Commun 353:946–952
Acknowledgments
The authors acknowledge the grant support from National Cancer Institute and National Institute of Environmental Health Sciences Grants R03CA125768, U01CA/ES66572, P30ES009089, and P30ES10126; and awards from the Breast Cancer Research Foundation, and Women At Risk (WAR).
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shen, J., Gammon, M.D., Terry, M.B. et al. Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival. Breast Cancer Res Treat 134, 393–400 (2012). https://doi.org/10.1007/s10549-012-2058-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-012-2058-9